CoreySCutlerMD

Oncology • Boston, MA

Hematologic Oncology

Associate Professor, Medicine-Brigham & Women's Hospital, Harvard Medical School

Join to view full profile

Are you Dr. Cutler?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 83 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
44 Binney Streetd1b30
Danafarber Cancer Institute
Boston, MA 02115
Phone+1 617-632-5946

Fax+1 617-632-5168

Summary

Dr. Corey Cutler, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts, Vermont, and Florida. He is affiliated with Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Salem Hospital.

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2002
McGill University Faculty of MedicineClass of 1996

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 1999 - 2026
VT State Medical License 2023 - 2026
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01
Completed
Phase 3
Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease Start of enrollment: 2004 Jan 01
Completed
Phase 1, Phase 2
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation Start of enrollment: 2003 Nov 01
Completed
Phase 2
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation Start of enrollment: 2002 Jul 01
Completed
Phase 2
Rituximab for Prevention of Chronic GVHD Start of enrollment: 2006 Sep 01
Completed
Phase 1, Phase 2
Campath in Chronic GVHD Start of enrollment: 2007 Jul 01
Completed
Phase 1
Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation Start of enrollment: 2007 Oct 01
Terminated
Phase 2
Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. Start of enrollment: 2011 Jan 01
Completed
Phase 1
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease Start of enrollment: 2010 Oct 01
Terminated
Phase 2
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease Start of enrollment: 2011 Mar 01
Completed
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Reduced Intensity Double Umbilical Cord Blood Transplantation Start of enrollment: 2011 Dec 01
Completed
Phase 2
Brentuximab Vedotin for Steroid Refractory GvHD Start of enrollment: 2012 Jul 01
Completed
Phase 1
The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. Start of enrollment: 2012 Jul 01
Terminated
Phase 2
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation Start of enrollment: 2012 Feb 01
Recruiting
Phase 2
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102) Start of enrollment: 2013 Dec 16
Completed
Phase 2
Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT Start of enrollment: 2014 Apr 01
Terminated
Phase 1
An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease Start of enrollment: 2014 Jul 01
Terminated
Phase 2
Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD Start of enrollment: 2015 Jan 01
Completed
Phase 2
Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study Start of enrollment: 2020 Jun 29
Recruiting
Join now to see all

Publications & Presentations

PubMed

Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation: A Randomized Clinical Trial.
Gregory A Abel, Haesook T Kim, Ira Zackon, Edwin T Alyea, Alexandra S Bailey
JAMA Oncology. 2025-01-09
Donor Type Does Not Impact Late Graft Failure Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Based Gra...
Cindy Lynn Hickey, Mei-Jie Zhang, Mariam Allbee-Johnson, Rizwan Romee, Navneet S Majhail
Transplantation and Cellular Therapy. 2025-01-02
Prehabilitation Exercise Training to Target Improved Muscle Strength in Pretransplant Patients Diagnosed With Multiple Myeloma: Protocol for a Pilot Randomized Control...
Amber J Normann, Clifton C Mo, Rebekah L Wilson, Michelle Perez, Corey Cutler
JMIR Research Protocols. 2024-12-19

Press Mentions

FDA Approves Treatment for Chronic Graft Versus Host DiseaseSeptember 6th, 2024
Notice of Compliance Issued Regarding Rezurock(TM) (Belumosudil Tablets)March 21st, 2023
GVHD Alliance to Honor Steven Pavletic with the Inaugural Lukas D. Wartman GVHD Achievement AwardFebruary 16th, 2023
Join now to see all